PGIM Jennison Health Sciences’ deep domain expertise and distinctive approach make for an attractive healthcare offering.
PGIM Jennison Health Sciences C PHLCX
- NAV / 1-Day Return 17.91 / +0.79 %
- Total Assets 1.8 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.980%
- Distribution Fee Level Average
- Share Class Type Level Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 64%
USD | NAV as of May 07, 2024 | 1-Day Return as of May 07, 2024, 10:24 PM GMT+0
Morningstar’s Analysis PHLCX
Will PHLCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 11.61 | 214.5 Mil | Healthcare |
Merck & Co Inc | 7.52 | 138.9 Mil | Healthcare |
AbbVie Inc | 6.61 | 122.1 Mil | Healthcare |
UnitedHealth Group Inc | 4.35 | 80.3 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.21 | 77.8 Mil | Healthcare |
Apellis Pharmaceuticals Inc | 3.67 | 67.8 Mil | Healthcare |
The Cigna Group | 3.45 | 63.7 Mil | Healthcare |
Becton Dickinson & Co | 3.15 | 58.2 Mil | Healthcare |
Boston Scientific Corp | 3.01 | 55.7 Mil | Healthcare |
Novo Nordisk A/S ADR | 2.92 | 53.9 Mil | Healthcare |